Consideration of genetic biomarkers can improve therapy of pediatric ALL: the role of TPMT genetic polymorphism on mercaptopurine induced toxicity in children with ALL has been clearly defined and clinical guidelines have been developed to tailor treatment with this medication on the basis of TPMT status. Here, TPMT is linked to acute lymphoblastic leukemia.